Foghorn Therapeutics (FHTX) Current Deferred Revenue (2020 - 2026)

Foghorn Therapeutics' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $52.3 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 1.22% year-over-year to $52.3 million; the TTM figure through Mar 2026 stood at $52.3 million (up 1.22% YoY), while the FY2025 annual figure was $43.2 million, down 5.29% from the prior year.
• Current Deferred Revenue was $52.3 million for Q1 2026 at Foghorn Therapeutics, up from $43.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $337.8 million in Q3 2023 to a low of $30.1 million in Q1 2022.
• Historically, Current Deferred Revenue has averaged $57.7 million across 5 years, with a median of $33.9 million in 2023.
• Biggest YoY gain for Current Deferred Revenue was 1508.68% in 2022; the steepest drop was 90.28% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $32.8 million in 2022, then climbed by 5.27% to $34.6 million in 2023, then jumped by 32.0% to $45.6 million in 2024, then slipped by 5.29% to $43.2 million in 2025, then grew by 21.09% to $52.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $52.3 million (Q1 2026), $43.2 million (Q4 2025), and $65.3 million (Q3 2025), per Business Quant data.